Quantum-Si to Report Second Quarter 2021 Financial Results on August 16, 2021
Quantum-Si announced the rescheduling of its second quarter 2021 financial results conference call to August 16, 2021, post-market close. CEO John Stark and CFO Claudia Drayton will host the call at 4:30 p.m. ET to discuss financial results and a business update. The call will be available via webcast on the Investor Relations website. Quantum-Si, founded in 2013, focuses on semiconductor chip-based proteomics, leveraging technology aimed at advancing drug discovery and diagnostics beyond DNA sequencing.
- The conference call aims to provide insights into the company's second quarter financial performance.
- Quantum-Si's innovative semiconductor chip technology positions it favorably in the growing proteomics market.
- The company's reliance on the success of its product development and regulatory approvals poses a risk to future performance.
- Forward-looking statements indicate significant uncertainties affecting actual results.
Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has rescheduled its conference call to report second quarter 2021 financial results to August 16, 2021, after market close.
John Stark, Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET on August 16, 2021, to discuss second quarter 2021 financial results and provide a business update.
The conference call will be broadcast live in listen-only mode via a webcast on Quantum-Si’s Investor Relations website at Events & Presentations.
Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:
US domestic callers: (844) 200-6205
Outside US callers: 44 (208) 0682 558
Access Code: 455685
After the live webcast, a replay of the call will be available until August 23, 2021 using the link posted to the Events & Presentations section of the website.
About Quantum-Si
Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of Quantum-Si Incorporated (the "Company") may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the proxy statement/prospectus relating to the business combination, including those under "Risk Factors" therein, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005264/en/
FAQ
When is Quantum-Si's second quarter 2021 earnings call?
How can I listen to Quantum-Si's earnings call?
What is the focus of Quantum-Si's technology?
What are the risks mentioned in Quantum-Si's press release?
Are there any significant uncertainties for Quantum-Si?
